Distinctive But Not Exceptional: The Risks of Psychedelic Ethical Exceptionalism

Area of Science:

• Bioethics
• Clinical Medicine
• Psychedelic Research

Background:

• Clinical use of psychedelics raises questions about ethical and evidentiary standards.
• Some propose these issues are exceptional, warranting different treatment for psychedelics.
• This contrasts with the view that psychedelics share commonalities with existing medical interventions.

Purpose of the Study:

• To evaluate the concept of "psychedelic ethical exceptionalism."
• To draw parallels with historical debates, such as genetic exceptionalism.
• To advocate for uniform ethical and evidentiary standards in clinical medicine.

Main Methods:

• Comparative ethical analysis.
• Review of bioethical literature on exceptionalism.
• Argumentation based on parallels with genetic exceptionalism debates.

Main Results:

• The concept of "psychedelic ethical exceptionalism" carries significant risks.
• Psychedelics share more in common with existing medical interventions than initially perceived.
• Appealing to psychedelic uniqueness is an insufficient justification for altering ethical standards.

Conclusions:

• Consistent ethical rules and evidentiary standards should be applied across all clinical medicine.
• The alleged uniqueness of psychedelics does not justify differential treatment.
• Any necessary changes to standards should be based on broader considerations, not exceptionalism.